ORBITAL IMPLANT

• US 20090309274A1
• Filed: 08/20/2009
• Published: 12/17/2009
• Est. Priority Date: 10/30/2001
• Status: Abandoned Application

• Current Assignee: Eyeborn (Proprietary) Limited
• Original Assignee: Eyeborn (Proprietary) Limited
• Inventors: Talma, Jan, Roux, Paul, Richter, Paul Wilhelm, Thomas, Michael Edward, Coetzee, Gert Hendrik Jacobus, Levitz, Lewis Mark, Minnaar, Mark, Gous, Petrus Nicholas Jacobus
• Application Number:
  US12/544,844
• Publication Number:
  US 20090309274A1
• Time in Patent Office: Days
• US Class Current: 264/628
• CPC Class Codes: A61F 2/141 Artificial eyes
• CPC Class Codes: C04B 2111/00836 for medical or dental applications
• CPC Class Codes: C04B 2235/5436 micrometer sized, i.e. from 1 to 100 micron
• CPC Class Codes: C04B 2235/6021 Extrusion moulding
• CPC Class Codes: C04B 2235/6022 Injection moulding
• CPC Class Codes: C04B 35/447 based on phosphates , e.g. hydroxyapatite
• CPC Class Codes: C04B 38/00 Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof treating slag with gases or gas generating material C04B5/06 ; expanded graphite C04B35/536
• CPC Class Codes: C04B 38/0054 the pores being microsized or nanosized

Abstract

An orbital implant includes a body of bioactive material having macropores of at least 400 μm, and a cap of bioactive material having substantially no pores or only micropores smaller than 50 μm. The cap covers a portion of the body.

Claims

1. A process for manufacturing an orbital implant, the process comprising:

shaping a mixture A into a substantially spherical body having a depression in its surface, with the depression having a size and shape of an orbital implant cap, wherein the mixture A comprises a bioactive material in particulate form, a binder, and a particulate pore forming agent;

filling the depression with a mixture B to form a structure, wherein the mixture B comprises a bioactive material and a binder;

consolidating the structure to form a spherical compact wherein the mixture B in the depression is coupled to the mixture A of the spherical body; and

sintering the spherical compact to obtain a substantially spherical orbital implant comprising;

an implant body comprising bioactive material of the mixture A and having macropores of at least 400 μ

m as well as micropores smaller than 50 μ

m, with some macropores being in communication with the outer surface of the implant body and with adjacent macropores being interconnected by openings and/or passageways so that open paths to the outer surface of the implant body are thereby provided, and

a cap covering a portion of the implant body, the cap comprising bioactive material of the mixture B and having substantially no pores or only micropores smaller than 50 μ

m, wherein the cap is thin relative to the diameter of the orbital implant, and wherein the cap is embedded in the implant body.

2. The process of claim 1, wherein the bioactive material of the mixture B is the same as the bioactive material of the mixture A, and is hydroxyapatite.

3. The process of claim 2, wherein the shaping the mixture A into a substantially spherical body is effected by pressing, and wherein the consolidation of the structure into the spherical compact is effected by pressing.

4. The process of claim 2, wherein the sintering is effected at a temperature below 1000°

C.

5. The process of claim 1, wherein the orbital implant has a diameter of about 20 mm.

7. The process of claim 1, wherein the macropores in the implant body are substantially spherical and have diameters of at least 400 μ

m.

8. The process of claim 7, wherein the diameters of the macropores do not exceed 1000 μ

m.

9. The process of claim 1, wherein substantially no isolated or closed macropores are present in the implant body.

10. The process of claim 1, wherein the openings and/or passageways which interconnect adjacent macropores in the implant body have diameters greater than 50 μ

m.

11. The process of claim 1, wherein the macropores in the implant body occupy from 40% to 85% by volume of the implant body.

12. The process of claim 1, wherein a portion of the micropores in the implant body are of irregular shape, and have a maximum dimension smaller than 50 μ

m.

13. The process of claim 1, wherein a portion of the micropores in the implant body are substantially spherical, and

wherein a portion of the micropores in the implant body have diameters smaller than 50 μ

m.

14. The process of claim 1, wherein adjacent micropores in the implant body are interconnected by openings, and

wherein a portion of the micropores are interconnected to the macropores by openings.

15. The process of claim 14, wherein substantially no isolated or closed micropores are present in the implant body.

16. The process of claim 1, wherein a portion of the micropores in the implant body are of irregular shape and are in the form of interstitial spaces between incompletely sintered bioactive material particles,

wherein a portion of the micropores are of substantially spherical shape,

wherein irregular micropores interconnect adjacent spherical micropores, and

wherein irregular micropores interconnect spherical micropores to macropores.

17. The process of claim 16,

wherein the spherical micropores in the implant body are of substantially the same size,

wherein the irregular micropores are of substantially the same size, and

wherein the irregular micropores are smaller than the spherical micropores.

18. The process of claim 1, wherein the micropores occupy from 3% to 70% by volume of the macropore-free bioactive material of the implant body.

19. The process of claim 1, wherein the depression in the spherical body of mixture A is of circular concave form, and

wherein the cap comprises a circular concave disc integrated with the implant body.

20. The process of claim 1, wherein the depth of the depression in the spherical body of mixture A is no more than half the diameter of the spherical body, and

wherein the cap has a thickness no more than half the diameter of the orbital implant.